Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With a straight face, can you really repeat this under oath with threat of perjury ?
Well, if I'm in a Trial For My Life, I want to favor survival, re-start or not.
I do get your point as to why you say what you do about it, we simply have to agree RA's will be the judge of who wins, hopefully patients.
Being sued is common and not usually a big deal.
Legal complaints are different, as they usually have teeth behind them. Have not seen anything significant from this yet.
They can buy the furniture back later, with a 1% tax.
WOLF of WALL Street, it's a compliment. Who's afraid of a Big Bad Wolf ?? Your NWBO observations are sharp like sharp teeth on said wolf.
Saving Keytruda via reformulation I think is the Merck plan, not buying other companies.
There was an article about subcutaneous formulation a while back.
I recall a interview with a Merck rep who thought the reformulation was good enough for fresh patents. I don't have that interview, it's foggy memory, but I saw it.
The article from Fierce Bio is here.. https://www.fiercepharma.com/drug-delivery/merck-posts-early-clinical-data-subcutaneous-keytruda-setting-stage-for-further
Good point.
gus, one more MRK Options thought, not only did some one big buy them, but someone big Sold them, they will be motivated for those to expire worthless.
Related to reformulation of Keytruda ??
I know they are trying to make a subcutaneous formulation since the patent cliff 2028 is coming fast.
I'm betting a data drop could be due around then, as someone knows it. Or, as always, they maybe bought a bunch as "bait" to sell different strikes.(As Cramer says, 'you gotta get it on CNBC')
hyrgo "rescue medication"- WHY ?? Oh, becasue that is what you do to SAVE a LIFE...
All crossover's were on a "re-start" schedule for vaccination.
I don't call a "re-start schedule" a double does like you see it, but I get your point.
"All patients were allowed to receive DCVax-L following tumor progression/recurrence, as well as other approved treatments per local practice. All parties (investigators, patients and sponsor) remained blinded as to which treatment each patient had received prior to crossover. All patients who chose this option were given the active treatment on a re-start schedule with immunizations at Days 0, 10 and 20, and then months 2, 4 and 8, and every 6 months thereafter beginning with month 12, with Day 0 being the day of the first vaccination post progression. To date, DCVax-L has been shipped for 286 patients (86.4%) in the trial."
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
Are there some legal manuvers going on?
hope your minions are listening, including avxl.
Why do they drive on the wrong side of the road? It's a Different Country.
MHRA procedures differ from FDA procedures, thus, clinicaltrials.gov and .eu can be different.
I hope no one makes investment decisions splitting those differences.
LOL Pfizer CEO has Covid. Wait, so it doesn't work ??
Patients being Alive shows our DCVAX vaccine WORKS !! They should buy us. They are loaded with buyout cash.
https://www.cnn.com/2022/08/15/health/pfizer-bourla-covid-positive/index.html
Disagree. Open Market order of, say, 500,000 shares would jack the price. I have noticed quick 10-15% bumps, quickly taken down of course, on simple 100k orders. So, it would be shrewd to buy the "C" for 'bigger' buyers. Waiting 90 days is nothing with this company's future. (yes, fingers and toes crossed over, lol)(yes, 90 days is nothing to wait for this company, lol, said it for you)
Primary Endpoint is OS.
https://clinicaltrials.gov/ct2/show/NCT00045968?term=dcvax&draw=2&rank=4
Outcome Measures
Go to sections
Primary Outcome Measures :
The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in newly diagnosed glioblastoma. [ Time Frame: Until death ]
Secondary Outcome Measures :
The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in recurrent GBM. [ Time Frame: Until death ]
Do you mean $620 worth versus $650, that is $30. Down the road, that is nothing. Just buy now and sit back.
30 minues in, vol = 50% entire day, based on 10 day avg volume.
Poeple, Canda/Advent was JUNE 23-ish.. Gosh
https://www.adventbio.uk/post/innovate-uk-s-global-business-innovation-programme-to-canada
"We were delighted to be part of Innovate UK's Global Business Innovation Programme to Canada focusing on Biomanufacturing of Advanced Therapies. "
And Kristyn Power was not there.
Explain the "second dose" again, like I'm a 3 year old.. I am confounded by the statement. Also, where that info comes from.
I'll bite, Define "Double Dosed" I don't know what you mean by it.
Why ratchet, TD just burns a building up?? I mean, some NWBO paper orders had to be there, right?
Could they not buy them, then after 90 days convert ? Better than placing a market order to get shares to cover a position or get shares to own so they can lend them out for income ????
true, would love one, but also, they must have a good reason for not holding yet, either way. Given they seem to be moving forward on UK side, I expect better than worse reasons.
Nah. ASM would be Nothing burger.
See video. All your answers are inside..
Scotty Doesn't Know.
Amen. try recommending happy call the company for factual, that gets deleted for either off-topic or personal attack... both might happen. ;)
Plan is to get price up so bear raid more effective.
Shares available to borrow is 2.6 million, was 950k a few days ago.
I suspect a bear raid soon.
https://fintel.io/ss/us/nwbo
Comedy gold is this...
No one is going to transcribe a phone call to Investor Relations, and put it out as a PR to be "sell the news". They are there to answer shareholder questions.
Fits some narratives. 'Poor communication' from the company, yet, all companies have shareholders contact investor's relations, all the time. Some Shareholders simply refuse to do so.
Perhaps Dave and Les says 'wow, shareholders never want to hear from us, the phone never rings and my email is empty. I guess they are happy'
Any Q' about company you should reach out directly.
Dave Innes
804-513-4758 dinnes@nwbio.com
Les Goldman
240-234-0059 lgoldman@nwbio.com
Your OWN Due Diligence will shine a light.
BULLSHIT. Les and Dave are very reliable.
TOTAL BULLSHIT.